Nintedanib as a new therapeutic agent for Duchenne muscular dystrophy: preclinical in vitro and in vivo studies

Pinol P.; Fernandez-Simon E.; Suarez X.; de Luna N.; Molins A.; de Oliva N.; Martinez A.; Escudero L.; Sanchez D.; Navarro X.; Illa I.; Gallardo E.; Diaz-Manera J.

首页> 外文期刊>Neuromuscular disorders: NMD >Nintedanib as a new therapeutic agent for Duchenne muscular dystrophy: preclinical in vitro and in vivo studies

【24h】

Nintedanib as a new therapeutic agent for Duchenne muscular dystrophy: preclinical in vitro and in vivo studies

机译：Nintedanib作为Duchenne肌营养不良的新治疗剂：临床前体外和体内研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Neuromuscular disorders: NMD》 |2017年第2期|共1页
作者
Pinol P.; Fernandez-Simon E.; Suarez X.; de Luna N.; Molins A.; de Oliva N.; Martinez A.; Escudero L.; Sanchez D.; Navarro X.; Illa I.; Gallardo E.; Diaz-Manera J.;
展开▼
作者单位

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Bellaterra Spain;

Univ Autonoma Barcelona Bellaterra Spain;

Univ Seville CSIC Hosp Univ Virgen del Rocio Seville Spain;

Univ Seville CSIC Hosp Univ Virgen del Rocio Seville Spain;

Univ Autonoma Barcelona Bellaterra Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

Univ Autonoma Barcelona Hosp Santa Creu &

Sant Pau Barcelona Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学;
关键词

相似文献

外文文献
中文文献
专利

1. Nintedanib as a new therapeutic agent for Duchenne muscular dystrophy: preclinical in vitro and in vivo studies [J] . Pinol P., Fernandez-Simon E., Suarez X., Neuromuscular disorders: NMD . 2017,第Suppla2期

机译：Nintedanib作为Duchenne肌营养不良的新治疗剂：临床前体外和体内研究
2. Src tyrosine kinase as potential drug target in Duchenne muscular dystrophy: in vivo and in vitro preclinical studies [J] . Sanarica F., Mantuano P., Cozzoli A., Neuromuscular disorders: NMD . 2017,第Suppla2期

机译：SRC酪氨酸激酶作为Duchenne肌营养不良的潜在药物靶标：体内和体外临床前研究
3. Src tyrosine kinase as potential drug target in Duchenne muscular dystrophy: in vivo and in vitro preclinical studies [J] . Sanarica F., Mantuano P., Cozzoli A., Neuromuscular disorders: NMD . 2017,第Suppla2期

机译：SRC酪氨酸激酶作为Duchenne肌营养不良的潜在药物靶标：体内和体外临床前研究
4. A New Synthesis of (+)-Negamycin and Its Derivatives as a Potential Therapeutic Agent for Duchenne Muscular Dystrophy Treatment [C] . Yoshio Hayashi, Shigenobu Nishiguchi, Magne O. Sydnes American Peptide Symposium . 2009

机译：（+） - 尼蛋白及其衍生物的新合成作为杜南肌营养不良治疗的潜在治疗剂
5. The therapeutic potential of the CRISPR-Cas9 system for treating Duchenne Muscular Dystrophy [D] . Rubin, David. 2016

机译：CRISPR-Cas9系统在治疗杜兴氏肌营养不良症中的治疗潜力
6. Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents [O] . Steve D Wilton, Sue Fletcher 2011

机译：用于治疗杜氏肌营养不良症的新型化合物：新兴治疗剂
7. Therapeutic approach design for Duchenne muscular dystrophy : autologous ex vivo cell therapy and in vivo gene therapy [O] . González Ramos Ana 2015

机译：杜氏肌营养不良症的治疗方法设计：自体离体细胞治疗和体内基因治疗

Nintedanib as a new therapeutic agent for Duchenne muscular dystrophy: preclinical in vitro and in vivo studies

著录项

相似文献

相关主题

期刊订阅